Danna nan don nuna banners ɗin ku akan wannan shafin kuma ku biya kawai don nasara

Labaran Waya

Sabbin Sabuntawa Akan Ingantacciyar Magance Against Cancer Cells

Written by edita

Hoth Therapeutics, Inc. a yau ta sanar da sabuntawa na ci gaba don novel cancer therapeutics, HT-KIT. Sabuwar hanyar Hoth, wacce ke amfani da sinadari-tsayayyen antisense oligonucleotide don niyya KIT na proto-oncogene ta hanyar tsara kwafin KIT mRNA, yana da yuwuwar warkewar KIT da aka yi niyya kaɗai, ko a haɗe tare da wakilai waɗanda ke niyya da siginar KIT, a cikin jiyya. Malignancies masu alaƙa da KIT.

Ta hanyar yarjejeniyar bincike na kimiyya da aka ba da tallafi tare da Jami'ar Jihar North Carolina, ƙungiyar ta yi amfani da tsarin canza tsarin HT-KIT mRNA akan ƙwayoyin cutar sankarar bargo a cikin vitro kuma sun gano cewa an rage furcin furotin KIT, sigina da aiki. Jiyya tare da HT-KIT ya hana ci gaban kwayar cutar kansa da haifar da mutuwar tantanin halitta sama da awanni 72. A cikin samfurin linzamin kwamfuta na mast cell leukemia, haɓakar ƙari da shigar da wasu gabobin sun ragu kuma mutuwar ƙwayar ƙwayar cuta ta ƙaru lokacin da HT-KIT ta haifar da frameshifted c-KIT mRNA.

Hoth ya shigar da aikace-aikacen hannu da yawa don kare wannan IP a duk faɗin duniya. 

"Tare da magungunan mu na HT-KIT, muna jujjuya siginar cutar kansa mai mahimmanci wanda ke da hannu a cikin cututtukan daji masu yawa, irin su mastocytosis na tsarin jiki, cutar sankarar jini ta mast cell, ciwace-ciwacen hanji da kuma cutar sankarar mahaifa. Hanyarmu tana guje wa tarzoma masu alaƙa da maye gurbin KIT ta hanyar niyya mRNA. Zagayen karatun mu na gaba yana gudana kuma muna farin cikin yin amfani da sakamakon taron Pre-IND da muka shirya da FDA daga baya a wannan shekara, "in ji Robb Knie, Babban Jami'in Hoth.

HT-KIT, sabon tsarin kwayoyin halitta, an sanya shi a matsayin Magungunan Marayu don maganin mastocytosis a farkon 2022. HT-KIT Hoth ya sami nasarar samar da yuwuwar samar da maganin HT-KIT tare da haɗin gwiwar WuXi STA.

FDA Orphan Drug Design an ba da ita ga hanyoyin kwantar da hankali na bincike da ke magance cututtukan likita da ba kasafai ba ko yanayin da ke shafar ƙasa da mutane 200,000 a Amurka. Matsayin magungunan marayu yana ba da fa'idodi ga masu haɓaka ƙwayoyi, gami da taimako a cikin tsarin haɓaka magunguna, ƙididdige ƙididdiga na haraji don farashin asibiti, keɓancewa daga wasu kuɗaɗen FDA da shekaru bakwai na keɓancewar tallace-tallace bayan amincewa.

Game da marubucin

edita

Edita a shugaba na eTurboNew ita ce Linda Hohnholz. Ta dogara ne a HQ eTN a Honolulu, Hawaii.

Leave a Comment

Share zuwa...